PR Newswire
11 Jan 2023, 11 GMT+10
![]() |
GENEVA, Jan. 11, 2023 /PRNewswire/ -- SELUTION SLR, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions.
This comes less than eight months after the company received its first IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications; as well as occlusive disease of the superficial femoral artery (SFA); and coronary In-Stent Restenosis (ISR).
Enrollment of the SELUTION SLR coronary de novo study will begin in the US within the next few months.
This will complement the substantial experience that the company has already gained with the SELUTION DeNOVO trial in Europe (ClinicalTrials.gov Identifier: NCT04859985). More than 800 patients of the 3,326 planned have been enrolled in this ground-breaking coronary randomized controlled study comparing SELUTION SLR vs. any limus drug-eluting stent (DES). The study is powered to demonstrate superiority of SELUTION SLR drug-eluting balloon (DEB) over DES in coronary de novo artery disease. This is the largest DEB study ever initiated and has the potential to change medical practice where implants (metal stents) have been the standard of care for more than 30 years.
"Treatment of de novo coronary arteries with drug-eluting balloons is a breakthrough in revascularization of coronary artery disease. The SELUTION SLR coronary de novo study is the first of its kind in the USA and will provide important data on the efficacy and safety of sirolimus- eluting balloon as a viable alternative to drug-eluting stent, leaving nothing behind post-PCI and eliminating in-stent restenosis and related complications," said Dr. Ron Waksman, Professor of Cardiology at Georgetown University, Director of Cardiovascular Research at MedStar Heart and Vascular Institute, Washington DC and Chairman of the MedAlliance Coronary Study Steering Committee.
"Coronary de novo lesions are the largest potential opportunity for use of DEB's: the data has shown clearly that DES don't work well in small vessels, long, or bifurcated lesions or in patients with diabetes or risk of high bleeding complications. These patients represent 60% of all patients currently treated with DES, who may now benefit from this exciting new DEB technology," added Jeffrey B. Jump, Chairman and CEO of MedAlliance.
SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in May 2020.
MedAlliance's unique DEB technology involves MicroReservoirs which contain a mixture of biodegradable polymer intermixed with the anti-restenotic drug sirolimus applied as a coating on the surface of an angioplasty balloon. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days.
SELUTION SLR 014 PTCA is commercially available in Europe, Asia, the Middle East and the Americas (outside USA) and most other countries where the CE Mark is recognized. Over 10,000 coronary units have already been used for patient treatment in routine clinical practice or as part of clinical trials.
About MedAlliance
MedAlliance is a medical technology company which announced a staged acquisition by Cordis in October 2022. It is headquartered in Nyon, Switzerland, MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. For further information visit: www.medalliance.com
Get a daily dose of Asia Pacific Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Pacific Star.
More InformationDHAKA, Bangladesh - According to Foreign Minister Dr. AK Abdul Momen, Bangladesh and the United States believe in democracy and ...
Naypyitaw, Myanmar - The Tatmadaw, Myanmar's military, showcased its prowess at the 31st ASEAN Armies Rifle Meet (AARM) held in ...
DHAKA, Bangladesh - The next general election may be rescheduled if the BNP wishes to participate, according to Chief Election ...
KATHMANDU, Nepal - The government has announced plans to hold the Third Investment Summit in Kathmandu on April 21-22 next ...
ISLAMABAD, Pakistan - Anwaar-ul-Haq Kakar, the caretaker prime minister, arrived in Abu Dhabi on Sunday for an official visit to ...
BANGKOK, Thailand: In response to heightened Chinese activity in the South China Sea, the United States and the Philippines have ...
NEW YORK, New York - Retreating bond yields and a higher-then-expected GDP reading for the third quarter boosted U.S. stocks ...
WASHINGTON D.C.: President Joe Biden invoked a Cold War-era act this week to boost investment in U.S. manufacturing of medicines ...
NEW DELHI, India: On November 24, the Economic Times (ET) reported that Tesla is ready to invest up to $2 ...
NEW YORK, New York - U.S. stocks closed in positive territory despite a volatile day Tuesday. Spending much time in ...
WASHINGTON D.C.: On November 24, the U.S. Food and Drug Administration (FDA) recalled three more brands of whole and pre-cut ...
DETROIT, Michigan: US electric vehicle (EV) sales are expected to reach a record of 9% of all passenger vehicles this ...